Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

ATL-001 (Ciclopirox oral solution)

Phase 2Small molecule

AAtlas Molecular Pharma

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Skin LesionsRecruiting

Skin LesionsPhase 2

Recruiting

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

Skin Lesions

NCT07024316

Clinical

Trials by Indication[1]

Skin Lesions1 trial

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

Recruiting·AAtlas Molecular Pharma·Phase 1/2·NCT07024316·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ATL-001 (Ciclopirox oral solution). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ATL-001 (Ciclopirox oral solution) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ATL-001 (Ciclopirox oral solution). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Atlas Molecular Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAtlas Molecular Pharma

Related News